The CCNB2 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout population in the A-549 human lung adenocarcinoma cell line, targeting the CCNB2 gene that encodes cyclin B2. This heterogeneous pool of gene-disrupted cells serves as a loss-of-function model suitable for investigating the role of cyclin B2 in cell cycle progression and lung cancer biology. As a polyclonal population, it maintains genetic diversity while collectively representing targeted gene disruption, enabling robust functional assays in a physiologically relevant epithelial cancer background.
A-549 cells, originally derived from a human lung adenocarcinoma, serve as a widely used model in cancer research for studying tumor biology, signaling pathways, and drug sensitivity. Their adherent epithelial morphology, well-characterized transcriptome, and accessibility to molecular tools make them an ideal host for gene-editing studies. These cells harbor mutations in key tumor suppressors, including p53, reflecting the genetic complexity of non-small cell lung cancer. Consequently, knockout models in A-549 provide a relevant platform to dissect gene functions associated with lung adenocarcinoma progression and therapy resistance.
CCNB2 encodes cyclin B2, a critical regulatory subunit that partners with cyclin-dependent kinase 1 (CDK1) to orchestrate the G2/M transition. The cyclin B2?CCDK1 complex is activated by CDC25C phosphatase and inhibited by WEE1 kinase, ensuring precise mitotic timing. Upstream, CCNB2 transcription is driven by FOXM1, NF-Y, and E2F1, and repressed by p53 via p21. Once active, the complex phosphorylates downstream targets such as Lamin B and Histone H1, facilitating nuclear envelope breakdown and chromatin condensation. The anaphase-promoting complex/cyclosome (APC/C), in association with CKS2, targets cyclin B2 for degradation, permitting mitotic exit. Additional regulators like PLK1 further modulate CDK1 activity, embedding cyclin B2 in a network that links growth signals to mitotic entry.
In the A-549 adenocarcinoma context, disruption of CCNB2 disrupts the mitotic machinery, potentially impairing G2/M progression, delaying mitotic entry, and reducing proliferation. Given frequent cell cycle checkpoint deregulation in lung cancer, this knockout model dissects cyclin B2-dependent mechanisms driving uncontrolled division. It may unveil alternative mitotic pathways, compensatory cyclin functions, or synthetic lethal interactions, aiding identification of therapeutic vulnerabilities. Moreover, since CCNB2 overexpression occurs in various tumors, this model facilitates exploring cyclin B2 as an anti-cancer target within a lung adenocarcinoma background.
Researchers can utilize this polyclonal knockout population in diverse assays. Flow cytometry with propidium iodide or BrdU labeling enables cell cycle phase analysis, while Western blotting assesses changes in cyclin B2, CDK1, and downstream phospho-targets. RT-qPCR quantifies CCNB2 mRNA, and immunofluorescence for phospho-histone H3 serves as a mitosis marker. Co-immunoprecipitation probes CDK1 interactions, and proliferation and drug sensitivity assays evaluate functional consequences. This model provides a comprehensive toolkit for advancing mitotic regulation and lung adenocarcinoma studies. For further information, contact Ascent Research.
